Johnson & Johnson Shares Dip 1.2% Amid Market Volatility

The healthcare giant faces mixed analyst ratings as investors weigh its growth prospects.

Apr. 10, 2026 at 9:48pm

Got story updates? Submit your updates here. ›

An extreme close-up of intricate, metallic banking machinery and gears, conveying a sense of institutional financial power and security without using any literal financial symbols or text.As Johnson & Johnson's stock price fluctuates, the company's diversified healthcare operations remain a bellwether for broader industry trends.New Brunswick Today

Shares of Johnson & Johnson (NYSE:JNJ) traded down 1.2% during Friday's trading session, with the stock reaching a low of $237.91 before closing at $238.34. Trading volume was down 15% from the average daily volume, as the company faced a mixed bag of analyst ratings and price target adjustments.

Why it matters

As a bellwether for the healthcare sector, Johnson & Johnson's stock performance is closely watched by investors. The company's diversified business across pharmaceuticals, medical devices, and consumer products makes it a barometer for broader industry trends and sentiment.

The details

Several research analysts have recently issued reports on Johnson & Johnson. TD Cowen assumed coverage on the company with a 'buy' rating and a $250 price target. However, Wall Street Zen downgraded the stock from 'buy' to 'hold'. Meanwhile, Weiss Ratings reiterated a 'buy (b)' rating, and HSBC increased its price target from $265 to $280, also maintaining a 'buy' recommendation.

  • Johnson & Johnson's shares traded down 1.2% during mid-day trading on Friday, April 10, 2026.
  • The company reported its latest quarterly earnings on Saturday, January 31, 2026.

The players

Johnson & Johnson

A multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and consumer health.

TD Cowen

An investment research firm that recently assumed coverage on Johnson & Johnson with a 'buy' rating and $250 price target.

Wall Street Zen

An investment research firm that recently downgraded Johnson & Johnson from 'buy' to 'hold' rating.

Weiss Ratings

An investment research firm that reiterated a 'buy (b)' rating on Johnson & Johnson.

HSBC

A global banking and financial services organization that increased its price target on Johnson & Johnson from $265 to $280, maintaining a 'buy' recommendation.

Got photos? Submit your photos here. ›

What they’re saying

“We must maintain a 'buy' rating on Johnson & Johnson given the company's strong fundamentals and growth prospects across its diversified healthcare business.”

— Analyst

“While Johnson & Johnson remains a solid healthcare player, we see near-term headwinds that warrant a 'hold' rating at this time.”

— Analyst

What’s next

Investors will be closely watching Johnson & Johnson's next earnings report, scheduled for late July 2026, for any updates on the company's financial performance and outlook.

The takeaway

Johnson & Johnson's stock dip reflects the mixed sentiment among analysts regarding the company's growth potential amidst a volatile market environment. As a diversified healthcare leader, the company's performance is seen as a barometer for the broader industry, making its stock movements a key indicator to monitor.